attention deficithyperactivity disorder and coexisting substance use disorder epidemiology and clinical presentation Mirjana Delić MD Attentiondeficithyperactivity disorder ADHD is a neurodevelopmental condition characterised by persistent patterns of inattention andor hy ID: 314269
Download Presentation The PPT/PDF document "A dult" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Adult attention – deficit/hyperactivity disorder and co-existing substance use disorder: epidemiology and clinical presentation
Mirjana Delić, MDSlide2
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition characterised by persistent patterns of inattention and/or hyperactivity and impulsiveness that can lead to severe disruptive behaviour
.1
Not only
a childhood disorder
.
2-3
APA. Diagnostic and Statistical Manual of Mental Disorders –
Text Revision. 4
th
Edn
. Washington DC: APA;
2000;
85–93.
Asherson
.
Expert Rev
Neurother
2005;5:525–39.
Elia
et al.
N
Engl
J Med
1999;340:780–8. Slide3
ADHD has an adult prevalence rate of 2–5%.1,2
There is an estimated 40–60% persistence into adulthood
(the full blown or in „partial remission“).
3
By adulthood there is a 1.5:1 M/F ratio of ADHD, and it is thought that females are likely to be underdiagnosed
.
1
A common reason for patient referral is that their child is diagnosed with ADHD first
(20% of parents of children with ADHD will have ADHD themselves).3
Kooij et al.
BMC Psychiatry
2010;10:67.
Fayyad et al.
Br J Psychiatry
2007;190:402–9.
Faraone
et al.
Psych Med.
2006;36:159
–
165Slide4
Worldwide Prevalence of ADHD in AdultsAccording to the 2007 WHO-WMH survey initiative, the estimated worldwide prevalence of adult ADHD is 3.4%
a
Upper end of 95% CI is below the prevalence estimate for total sample
b
Lower end of 95% CI is above the prevalence estimate for total sample
Country
Prevalence, % (SE)
n
Belgium
4.1 (1.5)
486
Colombia
1.9 (0.5)
a1,731France7.3 (1.8)b727Germany3.1 (0.8)621Italy2.8 (0.6)853Lebanon1.8 (0.7)a595Mexico1.9 (0.4)a1,736The Netherlands5.0 (1.6)516Spain1.2 (0.6)a960USA5.2 (0.6)3,197Total3.4 (0.4)11,422
Fayyad et al.
Br J Psychiatry
2007;190:402–9.Slide5
ADHD most likely has a multifactorial aetiology, including a combination of genetic and environmental risk factors:
-Approximately 80% of ADHD aetiology is linked to genetic factors
-
Various environmental factors
may also contribute
as secondary causes
Potential Aetiological Factors
Associated with ADHD
Group
Timing
Aetiological
Factors
Genetic
Mutations in the dopamine receptor and dopamine transporter genesEnvironmentalPrenatalDevelopmental cerebral abnormality, chromosome anomaly, virus, anaemia, hypothyroidism, iodine deficiency, exposure to drugs of abuse (e.g. nicotine) PerinatalPrematurity, low birth weight, anoxic-ischaemic encephalopathy, meningitis, encephalitisPostnatalViral meningitis, encephalitis, cerebral trauma, thyroid dysfunctionPotential Aetiological Factors Associated with ADHDMillichap. Pediatrics 2008;121:e358–65.Slide6
Impact of ADHD Beyond Core SymptomsFamily
Prone to emotional outbursts
6,11
Feels demoralized over constant
failure
6,11
Low self esteem
6,11
More chaotic personal and family routines11 Higher
rate of parental
divorce/separation
12,13
2-4 x
sibling fights14Leibson et al. 2001. Hodgkins et al. 2011.Sobanski et al. 2012. Barkley et al. 1996. Searight et al. 2000. Weiss et al. 1999. Birnbaum et al. 2005. Biederman et al. 1998. Milberger et al.1997. Pomerleau et al.1995. Brown and Pacini. 1989. Manuzza et al.1997. Secnik et al. 2005. Slide7
Disorganisation (“doesn’t plan ahead”)
Forgetfulness (“misses appointments, loses things”)
Procrastination (“starts projects but can’t complete”)
Time management problems (“always late”)
Premature shifting of activities (“starts something but then quickly distracted by something else”)
Impulsive decisions (especially around spending, taking on projects, travelling,
jobs or social plans)
Criminal offences (speeding, illegal drugs)
Unstable jobs and relationships
Clinical Presentation in Adults
Kooij
&
Francken
. DIVA Foundation 2010.Slide8
Inattention
Over-activity
Impulsiveness
Ceaseless mental activity (distracted mind)
Mood lability / emotional dysregulation
Low tolerance of frustration
Low self-esteem
Variable performance
DSM
criteria
(core symptoms)
Associated
SymptomsCommon SymptomsAsherson. 1st European Network Adult ADHD Conference. London, 2011.Slide9
Inability to relax
Restless sleep
Excessively active lifestyle
Constant purposeless motion of extremities
Stimulus seeking or anti-social behaviours
Hyperactivity-related
p
roblems
Epstien
J, Johnson D,
Conners
CK.
Conners Adult ADHS Diagnostic Interview for DSM IV. North Towanda, NY: Multi-Health Systems; 1999)Slide10
Disinhibited behaviour
Alcohol, cannabis, cocaine, tobacco, caffeine abuse
Family violence
Speaking out or making decisions without considering
Impulsivity-related
p
roblems
Epstien
J, Johnson D,
Conners
CK.
Conners
Adult ADHS
Diagnostic Interview for DSM IV. North Towanda, 1999.Slide11
Disorganisation and inefficiency
Procrastination
Failure to plan ahead
Forgetfulness
Difficulty in multitasking
Misjudging how long it takes to perform tasks
Inability to complete tasks
Distractibility
Poor ability to follow long explanations
Inattention-related
p
roblems
Epstien
J, Johnson D, Conners CK. Conners Adult ADHS Diagnostic Interview for DSM IV. North Towanda, NY: Multi-Health Systems; 1999.Asherson. 1st European Network Adult ADHD Conference. London, 2011 Slide12
The essential feature of ADHD is a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequently displayed and more severe
than is typically observed in individuals at a comparable level of development
Several inattentive or hyperactive-impulsive symptoms were present prior to age 12 years
Several symptoms are present in at least 2 settings
(e.g. home, work, school, with friends-relatives, other activities)
Symptoms interfere with social, occupational, and/or academic functioning
Symptoms not due to another mental disorder
Diagnosing ADHD: DSM-5 Criteria
APA. Diagnostic and Statistical Manual of Mental Disorders 5th Edn. Washington DC: APA; 2013;59–60. Slide13
Presentations:
-Combined
-
Predominantly inattentive
-
Predominantly hyperactive-impulsive
Inattention (at least 5 symptoms for age
>
17)Hyperactivity-impulsivity (at least 5 symptoms for age >
17)
-
ADHD in 'partial remission‘
-
Mild, Moderate, or Severe depending on few, intermediate, or many symptoms in excess of requirements, and minor, intermediate, or marked impairment, respectivelyClassifying ADHD: DSM-5 Criteria1APA. Diagnostic and Statistical Manual of Mental Disorders 5th Edn. Washington DC: APA; 2013;59–60Slide14
1: Clinical diagnostic interview:
Evaluate each of the 18 items (DSM/ICD) both currently and retrospectively,
and screen for comorbid disorders
2: Evaluation of impairments/needs:
Matching symptoms to impairments is key to the diagnosis
(developmental history important)
3: Screening instruments
Used to screen for ADHD and monitor treatment response
(Adult ADHD Self-Report Scale)
4: Psychometric tests:
Not sufficiently predictive, but a useful addition to the assessment (includes:
IQ-specific reading/mathematics difficulties, slow and variable responses,
response inhibition, working memory, choice
impulsivity)Diagnostic MethodsAsherson. 1st European Network Adult ADHD Conference. London, 2011.Slide15
Adult ADHD Treatments
Assess the relative severity of the substance use disorder (SUD)
, the symptoms of ADHD, and any other comorbid disorders. S
tabilizing
or addressing the
SUD should be the first priority when treating an adult with
SUD
and ADHD
.1. 1. Wilens TE. J Clin Psychiatry. 2004;65 Suppl 3:38-45Slide16
Multimodal Approach to Treatment Treatment should include:
- Pharmacotherapy
- Non-pharmacological treatment
Ps
ychoeducational
Psychological
PsychosocialSlide17
The clinician should begin pharmacotherapy with medications that have little likelihood of diversion or low liability, such as bupropion and atomoxetine, and, if necessary, progress to the stimulants.
Careful monitoring of patients during treatment is necessary to ensure compliance with the treatment plan.
1
1. Wilens TE. J Clin Psychiatry.
2004;65 Suppl 3:38-45Slide18
PharmacotherapyStimulantsAtomoxetineAntidepressants (bupropion, desipramine)Antihypertensive medications: clonidine and guanafacine (impulsivity and hyperactivity)
Antinarcolepsy medication (modafinil)Stimulants are effective in about 70% of patients with ADHD; their use in some parts of Europe is still controversial in both children and adults.Slide19
Does stimulant medications increase the risk of substance abuse in adulthood?
Stimulant
therapy in childhood does not increase the risk for subsequent drug and alcohol abuse disorders later in life.
Growing evidence has shown that stimulants, particularly long-acting formulations, can be given safely and are not routinely abused in substance-abusing populations
.
Mariani and Levin, 2006, 2007; Wilens et al, 2008Slide20
Non-pharmacological TreatmentEducation of patients and their families (psychoeducation)
Psychological interventions (cognitive-behavioural therapy, family therapy)
Psychosocial
interventions
Supportive coaching
Marital/family counselling
Career counselling
Technology
School/workplace accommodationsAdvocacySlide21
ConclusionsThe age-dependent change in the presentation of ADHD symptomsPeople suffering from ADHD are often stereotyped as lazy, bad or agressive, or considered to have a behavioral or special needs problem rather than a mental health disorder that requires treatmentIdentification of comorbid conditions: mood, anxiety, psychotic, organic and SUD (in addition to personality, tic and autistic spectrum disorders)
Diagnosis should include a detailed account of the developmental history; external validationMultimodal tretmentSlide22
Thank you!